(NASDAQ: CBUS) Cibus's forecast annual revenue growth rate of 144.51% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Cibus's revenue in 2026 is $4,286,000.On average, 6 Wall Street analysts forecast CBUS's revenue for 2026 to be $626,377,389, with the lowest CBUS revenue forecast at $496,308,284, and the highest CBUS revenue forecast at $777,437,692. On average, 6 Wall Street analysts forecast CBUS's revenue for 2027 to be $1,175,354,500, with the lowest CBUS revenue forecast at $975,365,619, and the highest CBUS revenue forecast at $1,382,594,887.
In 2028, CBUS is forecast to generate $5,699,835,774 in revenue, with the lowest revenue forecast at $5,476,336,750 and the highest revenue forecast at $5,867,460,042.